• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make your clinical trials easier, faster, more engaging and accessible to all.

        • Enjoy flexible, fast and confidential site assessments at home.

        • Enhance your ePRO data with photo and audio capture.

        • Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Assess the capacity of the lungs for effective gas transfer.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • Study Endpoints
      • Cardiac Solutions
        • Cardiac Solutions
        • Arrhythmia Analysis
        • Blood Pressure Services
        • ECG — On-site to DCT and Phase I-IV
        • Phase I/TQT Cardiac Assessment
        • Regulatory Consultation and Statistical Analysis Expertise
      • Clinical Adjudication
      • eCOA
        • eCOA Clinical Trials
        • eCOA Live
        • eCOA Multimedia
        • eCOA Rapid Start
        • eCOA Rater and Participant Training
        • eCOA Rescue Studies
        • Suicidal Ideation
      • Medical Imaging
        • Medical Imaging
        • Image Redact AI
        • Imaging Platform
        • Medical Imaging Science Team
        • Modalities
        • SMART Submit
      • Precision Motion
        • Precision Motion for Clinical Trials
        • Precision Motion for Research
        • Precision Motion: Scientific Publications
      • Respiratory Solutions
        • Respiratory Solutions
        • Site-Based Spirometry
        • Virtual Home Spirometry
        • Cough and Lung Sounds
        • Diffusing Capacity (DLCO)
      • Trial Enablement
        • Trial Enablement
        • Eligibility Solution
        • Reporting & Analytics
        • Source Document Manager
    • Segments
      • Biotechs
      • CROs
      • Pharma
    • Study Phases
      • Phase I
      • Phase II/III
    • Technology
      • Artificial Intelligence (AI)
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Diabetes and Obesity
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
      • Dementias
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology
    • Ophthalmology
    • Respiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Blog Articles Researcher spotlight: Clayton Swanson

Researcher spotlight: Clayton Swanson

Precision Motion

Clayton Swanson, Ph.D.

– Research Assistant Professor, Department of Neurology, University of Florida

Opal® V2R Technology has been used by thousands of researchers worldwide and together, these researchers have published more than 800 peer reviewed papers, greatly contributing to available body of evidence in human movement.

APDM, now owned by Clario, has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world for more than 50 years. Our endpoint data solutions have been deployed over 26,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.

For more information, visit our Wearable Biosensors for Research page. 

Q:

Would you please introduce yourself, your academic background and your research interests?

A:

My name is Clayton Swanson, and I am a Research Assistant Professor in the Department of Neurology at the University of Florida, as well as a Research Health Scientist at the Brain Rehabilitation Research Center (BRRC) within the Malcom Randall VA Medical Center in Gainesville, Florida.

I earned my bachelor’s degree in Pre-Therapy and Allied Health from Oregon State University, followed by a master’s degree in health and Exercise Science and a Ph.D. in Neuromechanics from Colorado State University. I then completed a postdoctoral fellowship under the mentorship of Dr. David Clark at the BRRC, where I further developed my expertise in neurorehabilitation and mobility research.

My research focuses on understanding the neural mechanisms underlying mobility, particularly turning while walking, using multimodal neuroimaging tools. I am especially interested in translating these findings into effective, pragmatic neurorehabilitation strategies to enhance mobility and reduce barriers to optimal care, particularly for individuals with neurological conditions such as multiple sclerosis and older adults at risk for mobility decline.

Q:

Do you have a personal story that led to your interest in human movement/ neurodegenerative disease research? What continues to drive your ambitions as a scientist?

A:

My interest in human movement began during my time as a therapy aide at Oregon Health & Science University, where I became fascinated by how physical therapists determine the best treatments for different patients. This curiosity led me to work with Dr. Laurie King and Dr. Fay Horak in the Balance Disorders Laboratory, where I studied the effects of injury and disease on mobility. That experience laid the foundation for my research today.

I am particularly interested in understanding how the nervous system controls mobility and, more importantly, how we can apply that knowledge to develop targeted rehabilitation strategies for individuals experiencing mobility impairments. What keeps me excited about research is the potential to translate discoveries into meaningful, real-world interventions that improve mobility, independence, and quality of life for individuals with neurological conditions.

Q:

How has Clario’s APDM Opal V2R® System been most useful in your research endeavors?

A:

Clario’s APDM Opal system has been a fundamental tool in nearly every study I have conducted or collaborated on. There are several key reasons why I have integrated Opal sensors into my research. First, the system provides a valid and reliable means of capturing detailed spatiotemporal kinematics, which is critical for understanding mobility function. Second, its portability allows for data collection beyond traditional laboratory settings, enabling assessments in diverse environments and improving ecological validity. Lastly, over the past decade, I have received outstanding customer support, from sales to technical assistance, which has further reinforced my trust in the system.

Q:

What research projects or questions are you currently working on?

A:

I am currently exploring research questions related to the feasibility and acceptability of using Opal sensors for fully remote, telehealth-supported clinical mobility assessments. Specifically, I am interested in understanding how wearable sensor technology can be leveraged to assess mobility in individuals who face barriers to in-person care, such as those living in rural areas or with limited transportation access. My goal is to determine whether this approach can provide accurate, reliable assessments and ultimately improve accessibility to mobility evaluations for underserved populations.

Q:

Where do you see the use of wearable IMU’s in human movement research going in the next 5 years?

A:

Over the next few years, I anticipate that IMUs will continue to play a crucial role in human movement research. One promising direction is their integration with other wearable technologies, such as augmented reality, to provide adaptive, real-time biofeedback during both in-person and remote rehabilitation sessions. Additionally, advancements in artificial intelligence will likely enhance existing algorithms, enabling more precise and population specific movement analysis. These improvements could lead to the development of new metrics sensitive enough to assess fall risk, personalize rehabilitation strategies, and further expand individualized medicine.

Q:

Fill in the blank: When I’m not working on a research project, you can find me…

A:

When I’m not working, you can find me spending time with my wife and our two young boys, hanging out with friends, exploring parks and playgrounds, hiking, gardening, riding bikes, and staying active outside.

Check out Professor Swanson’s recent publication

Peer-Reviewed

Links between Neuroanatomy and Neurophysiology with Turning Performance in People with Multiple Sclerosis

Read

Learn more about Opal wearable sensors or be featured in an upcoming researcher spotlight

Contact Clario Precision Motion
Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Researcher spotlight: Dr. Lauren Tueth

Precision Motion

Read
Article

Researcher spotlight: Brice Cleland

Precision Motion

Read
Article

Researcher spotlight: Josefa Domingos

Precision Motion

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum